Molecular approaches to potentiate cisplatin responsiveness in carcinoma therapeutics

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Mitra AK, Agrahari V, Mandal A, et al. Novel delivery approaches for cancer therapeutics. J Control Release. 2015;219:248–268.
   PubMed Web of Science ®Google Scholar
• Kelland L. The resurgence of platinum-based cancer chemotherapy. Natl Rev Cancer. 2007;7(8):573–584.
   PubMed Web of Science ®Google Scholar
• Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378.
   PubMed Web of Science ®Google Scholar
• Stover EH, Konstantinopoulos PA, Matulonis UA, et al. Biomarkers of response and resistance to DNA repair targeted therapies. Clin Cancer Res. 2016;22(23):5651–5660.
   PubMed Web of Science ®Google Scholar
• Kumar A, Purohit S, Sharma NK. Aberrant DNA double-strand break repair threads in breast carcinoma: orchestrating genomic insults survival. J Cancer Prev. 2016;21(4):227–234.
   PubMedGoogle Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Chen X, Lu P, Wu Y, et al. MiRNAs-mediated cisplatin resistance in breast cancer. Tumour Biol. 2016;37(10):12905–12913.
   PubMed Web of Science ®Google Scholar
• Hall MD, Okabe M, Shen DW, et al. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol. 2008;48:495–535.
   PubMed Web of Science ®Google Scholar
• Eljack ND, Ma HY, Drucker J, et al. Mechanisms of cell uptake and toxicity of the anticancer drug cisplatin. Metallomics. 2014;6(11):2126–2133.
   PubMed Web of Science ®Google Scholar
• Basu A, Krishnamurthy S. Cellular responses to cisplatin-induced DNA damage. J Nucleic Acids. 2010;201367.
   PubMedGoogle Scholar
• Wee NK, Weinstein DC, Fraser ST, et al. The mammalian copper transporters CTR1 and CTR2 and their roles in development and disease. Int J Biochem Cell Biol. 2013;45(5):960–963.
   PubMed Web of Science ®Google Scholar
• Öhrvik H, Thiele DJ. The role of Ctr1 and Ctr2 in mammalian copper homeostasis and platinum-based chemotherapy. J Trace Elem Med Biol. 2015;31:178–182.
   PubMed Web of Science ®Google Scholar
• Jamieson E, Lippard S. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev. 1999;99:2467–2498.
   PubMed Web of Science ®Google Scholar
• Fong CW. Platinum anti-cancer drugs: free radical mechanism of Pt-DNA adduct formation and anti-neoplastic effect. Free Radic Biol Med. 2016;95:216–229.
   PubMed Web of Science ®Google Scholar
• Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265–7279.
   PubMed Web of Science ®Google Scholar
• Widlak P, Pietrowska M, Lanuszewska J. The role of chromatin proteins in DNA damage recognition and repair. Histochem Cell Biol. 2006;125:119–126.
   PubMed Web of Science ®Google Scholar
• Pasheva EA, Ugrinova I, Spassovska NC, et al. The binding affinity of HMG1 protein to DNA modified by cis-platin and its analogs correlates with their antitumor activity. Int J Biochem Cell Biol. 2002;34(1):87–92.
   PubMed Web of Science ®Google Scholar
• Elder RM, Jayaraman A. Sequence-specificrecognition of cancer drug-DNA adducts by HMGB1a repair protein. Biophys J. 2012;102(10):2331–2338.
   PubMed Web of Science ®Google Scholar
• Ramachandran S, Temple B, Alexandrova AN, et al. Recognition of platinum-DNA adducts by HMGB1a. Biochemistry. 2012;51(38):7608–7617.
   PubMed Web of Science ®Google Scholar
• Negureanu L, Salsbury FR. The molecular origin of the MMR-dependent apoptosis pathway from dynamics analysis of MutSα-DNA complexes. J Biomol Struct Dyn. 2012;30(3):347–361.
   PubMed Web of Science ®Google Scholar
• Wang X, Jiang P, Wang P, et al. EGCG enhances cisplatin sensitivity by regulating expression of the copper and cisplatin influx transporter CTR1 in ovary cancer. Samimi G, ed. PLoS ONE. 2015;10(4):e0125402.
   PubMed Web of Science ®Google Scholar
• Amable L. Cisplatin resistance and opportunities for precision medicine. Pharmacol Res. 2016;106:27–36.
   PubMed Web of Science ®Google Scholar
• Larson CA, Blair BG, Safaei R, et al. The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol. 2009;75(2):324–330.
   PubMed Web of Science ®Google Scholar
• Song I-S, Chen HHW, Aiba I, et al. Transcription factor Sp1 plays an important role in the regulation of copper homeostasis in mammalian cells. Mol Pharmacol. 2008;74(3):705–713.
   PubMed Web of Science ®Google Scholar
• Howell SB, Safaei R, Larson CA, et al. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol. 2010;77(6):887–894.
   PubMed Web of Science ®Google Scholar
• Aida T, Takebayashi Y, Shimizu T, et al. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a prognostic factor in human endometrial carcinoma. Gynecol Oncol. 2005;97(1):41–45.
   PubMed Web of Science ®Google Scholar
• Li YT, Chua MJ, Kunnath AP, et al. Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs. Int J Nanomedicine. 2012;7:2473–2481.
   PubMedGoogle Scholar
• Abada P, Howell SB. Regulation of cisplatin cytotoxicity by cu influx transporters. Metal-Based Drugs. 2010;2010:317581.
   PubMedGoogle Scholar
• Blair BG, Larson CA, Safaei R, et al. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of cisplatin and carboplatin. Clin Cancer Res. 2009;15(13):4312–4321.
   PubMed Web of Science ®Google Scholar
• Tadini-Buoninsegni F, Bartolommei G, Moncelli MR, et al. Translocation of platinum anticancer drugs by human copper ATPases ATP7A and ATP7B. Angewandte Chemie. 2014;53(5):1297–1301.
   Google Scholar
• Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615–627.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–1883.
   PubMed Web of Science ®Google Scholar
• Kothandapani A, Sawant A, Dangeti VSMN, et al. Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicity. Nucleic Acids Res. 2013;41(15):7332–7343.
   PubMed Web of Science ®Google Scholar
• Miyagawa K. Clinical relevance of the homologous recombination machinery in cancer therapy. Cancer Sci. 2008;99:187–194.
   PubMed Web of Science ®Google Scholar
• Xie SM, Fang WY, Liu Z, et al. Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008;6:55.
   PubMed Web of Science ®Google Scholar
• Fu J, Zhou J, Shi J, et al. Emodin affects ERCC1 expression in breast cancer cells. J Transl Med. 2012;10(Suppl 1):S7.
   PubMed Web of Science ®Google Scholar
• Fu S, Naing A, Fu C, et al. Overcoming platinum resistance through the use of a copper-lowering agent. Mol Cancer Ther. 2012;11(6):1221–1225.
   PubMed Web of Science ®Google Scholar
• Amable L, Fain J, Gavin E, et al. Gli1 contributes to cellular resistance to cisplatin through altered cellular accumulation of the drug. Oncol Rep. 2014;32(2):469–474.
   PubMed Web of Science ®Google Scholar
• Vaezi A, Wang X, Buch S, et al. XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2011;17(16):5513–5522.
   PubMed Web of Science ®Google Scholar
• Arora S, Kothandapani A, Tillison K, et al. Downregulation of XPF–ERCC1 enhances cisplatin efficacy in cancer cells. DNA Repair. 2010;9(7):745–753.
   PubMed Web of Science ®Google Scholar
• Ratner ES, Zhu YL, Penketh PG, et al. Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair. Br J Cancer. 2016;114(7):777–786.
   PubMed Web of Science ®Google Scholar
• Sawant A, Floyd AM, Dangeti M, et al. Differential role of base excision repair proteins in mediating cisplatin cytotoxicity. DNA Repair (Amst). 2017;pii: S1568-7864(16)30271-3.
   PubMed Web of Science ®Google Scholar
• Kothandapani A, Dangeti VSMN, Brown AR, et al. Novel role of base excision repair in mediating cisplatin cytotoxicity. J Biol Chem. 2011;286(16):14564–14574.
   PubMed Web of Science ®Google Scholar
• Sawant A, Kothandapani A, Zhitkovich A, et al. Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links. DNA Repair. 2015;35:126–136.
   PubMed Web of Science ®Google Scholar
• Sun XJ, Jiang TH, Zhang XP, et al. Role of the tumor microenvironment in pancreatic adenocarcinoma. Front Biosci (Landmark Ed). 2016;21:31–41.
   PubMed Web of Science ®Google Scholar
• Liang S, Peng X, Li X, et al. Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin. Oncotarget. 2015;6(2):1020–1030.
   PubMed Web of Science ®Google Scholar
• Li J, Jiang K, Qiu X, et al. Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer. BMB Rep. 2014;47(1):33–38.
   PubMed Web of Science ®Google Scholar
• Jung MJ, Rho JK, Kim YM, et al. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene. 2013;32(2):209–221.
   PubMed Web of Science ®Google Scholar
• Liang X-J, Mukherjee S, Shen D-W, et al. Endocytic recycling compartments altered in cisplatin-resistant cancer cells. Cancer Res. 2006;66(4):2346–2353.
   PubMed Web of Science ®Google Scholar
• Taromi S, Kayser G, Catusse J, et al. CXCR4 antagonists suppress small cell lung cancer progression. Oncotarget. 2016;7(51):85185–85195.
   PubMed Web of Science ®Google Scholar
• Yu ZH, Liu T, Zhao YH, et al. Cisplatin targets the stromal cell-derived factor-1-CXC chemokine receptor type 4 axis to suppress metastasis and invasion of ovarian cancer-initiating cells. Tumour Biol. 2014;35(5):4637–4644.
   PubMed Web of Science ®Google Scholar
• Yang S-X, Loo WT, Chow LW, et al. Decreased expression of C-erbB-2 and CXCR4 in breast cancer after primary chemotherapy. J Transl Med. 2012;10(Suppl 1):S3.
   PubMed Web of Science ®Google Scholar
• Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16(11):2927–2931.
   PubMed Web of Science ®Google Scholar
• Liang X-J, Meng H, Wang Y, et al. Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. Proc Natl Acad Sci USA. 2010;107(16):7449–7454.
   PubMed Web of Science ®Google Scholar
• Baffy G, Derdak Z, Robson SC. Mitochondrial recoupling: a novel therapeutic strategy for cancer? Br J Cancer. 2011;105(4):469–474.
   PubMed Web of Science ®Google Scholar
• Robbins D, Zhao Y. New aspects of mitochondrial uncoupling proteins (UCPs) and their roles in tumorigenesis. Int J Mol Sci. 2011;12(8):5285–5293.
   PubMed Web of Science ®Google Scholar
• Sayeed A, Meng Z, Luciani G, et al. Negative regulation of UCP2 by TGFβ signaling characterizes low and intermediate-grade primary breast cancer. Cell Death Dis. 2010;1(7):e53.
   PubMed Web of Science ®Google Scholar
• Pons DG, Nadal-Serrano M, Torrens-Mas M, et al. UCP2 inhibition sensitizes breast cancer cells to therapeutic agents by increasing oxidative stress. Free Radic Biol Med. 2015;86:67–77.
   PubMed Web of Science ®Google Scholar
• Lingeman RG, Hickey RJ, Malkas LH. Expression of a novel peptide derived from PCNA damages DNA and reverses cisplatin resistance. Cancer Chemother Pharmacol. 2014;74(5):981–993.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Marsili S, Vitale I, et al. Vitamin B6 metabolism influences the intracellular accumulation of cisplatin. Cell Cycle. 2013;12(3):417–421.
   PubMed Web of Science ®Google Scholar
• Yang M, Yuan F, Li P, et al. Interferon regulatory factor 4 binding protein is a novel p53 target gene and suppresses cisplatin-induced apoptosis of breast cancer cells. Mol Cancer. 2012;11:54.
   PubMed Web of Science ®Google Scholar
• Radin D, Lippa A, Patel P, et al. Lifeguard inhibition of Fas-mediated apoptosis: a possible mechanism for explaining the cisplatin resistance of triple-negative breast cancer cells. Biomed Pharmacother. 2016;77:161–166.
   PubMed Web of Science ®Google Scholar
• Sharma T, Hamilton R, Mandal CC. miR-214: a potential biomarker and therapeutic for different cancers. Future Oncol. 2015;1(2):349–363.
   Web of Science ®Google Scholar
• He H, Tian W, Chen H, et al. MiR-944 functions as a novel oncogene and regulates the chemoresistance in breast cancer. Tumour Biol. 2016;37(2):1599–1607.
   PubMed Web of Science ®Google Scholar
• Liu Y, Niu Z, Lin X, et al. MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1. Cancer Gene Ther. 2017;24(5):208–214.
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Hojo A, Yamane Y, et al. Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers. Chem Biol Interact. 2013;202(1–3):234–242.
   PubMed Web of Science ®Google Scholar
• Kwok J-M-M, Peck B, Monteiro LJ, et al. FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res. 2010;8(1):24–34.
   PubMed Web of Science ®Google Scholar
• Liang ZD, Tsai W-B, Lee M-Y, et al. Specificity protein 1 (Sp1) oscillation is involved in copper homeostasis maintenance by regulating human high-affinity copper transporter 1 expression. Mol Pharmacol. 2012;81(3):455–464.
   PubMed Web of Science ®Google Scholar
• Lin X, Shang X, Manorek G, et al. Integrin αV modulates the cellular pharmacology of copper and cisplatin by regulating expression of the influx transporter CTR1. Oncoscience. 2014;1(3):185–195.
   PubMedGoogle Scholar
• Liu J, Wang T, Wang D, et al. Smart nanoparticles improve therapy for drug-resistant tumors by overcoming pathophysiological barriers. Acta Pharmacologica Sinica. 2017;38(1):1–8.
   PubMed Web of Science ®Google Scholar
• Liang ZD, Long Y, Tsai W-B, et al. Mechanistic basis for overcoming platinum resistance using copper chelating agents. Mol Cancer Ther. 2012;11(11):2483–2494.
   PubMed Web of Science ®Google Scholar
• Larson CA, Adams PL, Blair BG, et al. The role of the methionines and histidines in the transmembrane domain of mammalian copper transporter 1 in the cellular accumulation of cisplatin. Mol Pharmacol. 2010;78(3):333–339.
   PubMed Web of Science ®Google Scholar
• Kuo MT, Fu S, Savaraj N, et al. Role of the human high-affinity copper transporter (hCtr1) in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. Cancer Res. 2012;72(18):4616–4621.
   PubMed Web of Science ®Google Scholar
• Zhou F, Feng B, Yu H, et al. Cisplatin prodrug-conjugated gold nanocluster for fluorescence imaging and targeted therapy of the breast cancer. Theranostics. 2016;6(5):679–687.
   PubMed Web of Science ®Google Scholar
• Tang F, Li L, Chen D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater. 2012;24(12):1504–1534.
   PubMed Web of Science ®Google Scholar
• Li M, Tang Z, Zhang Y, et al. Targeted delivery of cisplatin by LHRH-peptide conjugated dextran nanoparticles suppresses breast cancer growth and metastasis. Acta Biomater. 2015;18:132–143.
   PubMed Web of Science ®Google Scholar
• Díaz A, González ML, Pérez RJ, et al. Direct intercalation of cisplatin into zirconium phosphate nanoplatelets for potential cancer nanotherapy. Nanoscale. 2013;5(23):11456–11463.
   PubMed Web of Science ®Google Scholar
• Jiang P, Wu X, Wang X, et al. NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells. Oncotarget. 2016;7(28):43337–43351.
   PubMed Web of Science ®Google Scholar
• Lou J-S, Yan L, Bi CWC, et al. Yu Ping Feng San reverses cisplatin-induced multi-drug resistance in lung cancer cells via regulating drug transporters and p62/TRAF6 signaling. Sci Rep. 2016;6:31926.
   PubMed Web of Science ®Google Scholar
• Karasawa T, Steyger PS. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett. 2015;237(3):219–227.
   PubMed Web of Science ®Google Scholar
• Sengupta P, Basu S, Soni S, et al. Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc Natl Acad Sci USA. 2012;109(28):11294–11299.
   PubMed Web of Science ®Google Scholar
• Tsodikov OV, Ivanov D, Orelli B, et al. Structural basis for the recruitment of ERCC1-XPF to nucleotide excision repair complexes by XPA. EMBO J. 2007;26(22):4768–4776.
   PubMed Web of Science ®Google Scholar
• Gentile F, Tuszynski JA, Barakat KH. New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy. J Mol Graph Model. 2016;65:71–82.
   PubMed Web of Science ®Google Scholar
• Arora S, Heyza J, Zhang H, et al. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells. Oncotarget. 2016;7(46):75104–75117.
   PubMed Web of Science ®Google Scholar
• Alekseev S, Ayadi M, Brino L, et al. A small molecule screen identifies an inhibitor of DNA repair inducing the degradation of TFIIH and the chemosensitization of tumor cells to platinum. Chem Biol. 2014;21(3):398–407.
   PubMedGoogle Scholar
• Inoue A, Kikuchi S, Hishiki A, et al. A small molecule inhibitor of monoubiquitinated Proliferating Cell Nuclear Antigen (PCNA) inhibits repair of interstrand DNA cross-link, enhances DNA double strand break, and sensitizes cancer cells to cisplatin. J Biol Chem. 2014;289(10):7109–7120.
   PubMed Web of Science ®Google Scholar
• Wong SW, Tiong KH, Kong WY, et al. Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73. Breast Cancer Res Treat. 2011;128(2):301–313.
   PubMed Web of Science ®Google Scholar
• Shen D-W, Pouliot LM, Hall MD, et al. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Sibley DR, ed. Pharmacol Rev. 2012;64(3):706–721.
   PubMed Web of Science ®Google Scholar
• Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev. 2010;62(11):1064–1079.
   PubMed Web of Science ®Google Scholar
• Zhou L, Wang K, Li Q, et al. Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives. Expert Rev Proteomics. 2016;13(4):367–381.
   PubMed Web of Science ®Google Scholar
• Zhou S, Huang Q, Zheng S, et al. miR-27a regulates the sensitivity of breast cancer cells to cisplatin treatment via BAK-SMAC/DIABLO-XIAP axis. Tumour Biol. 2016;37(5):6837–6845.
   PubMed Web of Science ®Google Scholar
• Ye Z, Hao R, Cai Y, et al. Knockdown of miR-221 promotes the cisplatin-inducing apoptosis by targeting the BIM-Bax/Bak axis in breast cancer. Tumour Biol. 2016;37(4):4509–4515.
   PubMed Web of Science ®Google Scholar
• Cataldo A, Cheung DG, Balsari A, et al. miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response. Oncotarget. 2016;7(1):786–797.
   PubMed Web of Science ®Google Scholar
• Zhang R, Li Y, Dong X, et al. MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1 in breast cancer. Med Oncol. 2014;31(12):347.
   PubMed Web of Science ®Google Scholar
• O’Brien K, Lowry MC, Corcoran C, et al. miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. Oncotarget. 2015;6(32):32774–32789.
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2011;363(20):1938–1948.
   Web of Science ®Google Scholar
• De Laurentiis M, Cianniello D, Caputo R, et al. Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev. 2010;36(Suppl 3):S80–6.
   PubMed Web of Science ®Google Scholar
• Chen J, Dexheimer TS, Ai Y, et al. Selective and cell-active inhibitors of the USP1/UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. Chem Biol. 2011;18(11):1390–1400.
   PubMedGoogle Scholar
• Albarakati N, Abdel-Fatah TM, Doherty R, et al. Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy. Mol Oncol. 2015;9(1):204–217.
   PubMed Web of Science ®Google Scholar
• Pogribny IP, Filkowski JN, Tryndyak VP, et al. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer. 2010;127(8):1785–1794.
   PubMed Web of Science ®Google Scholar
• Popat A, Hartono SB, Stahr F, et al. Mesoporous silica nanoparticles for bioadsorption, enzyme immobilization, and delivery carriers. Nanoscale. 2011;3(7):2801–2818.
   PubMed Web of Science ®Google Scholar
• Kanwal R, Gupta S. Epigenetic modifications in cancer. Clin Genet. 2012;81(4):303–311.
   PubMed Web of Science ®Google Scholar
• Neher TM, Bodenmiller D, Fitch RW, et al. Novel irreversible small molecule inhibitors of replication protein a display single agent activity and synergize with cisplatin. Mol Cancer Ther. 2011;10(10):1796–1806.
   PubMed Web of Science ®Google Scholar
• Sourisseau T, Helissey C, Lefebvre C, et al. Translational regulation of the mRNA encoding the ubiquitin peptidase USP1 involved in the DNA damage response as a determinant of Cisplatin resistance. Cell Cycle. 2016;15(2):295–302.
   PubMed Web of Science ®Google Scholar
• Zhang C, Hong CS, Hu X, et al. Inhibition of protein phosphatase 2A with the small molecule LB100 overcomes cell cycle arrest in osteosarcoma after cisplatin treatment. Cell Cycle. 2015;14(13):2100–2108.
   PubMed Web of Science ®Google Scholar
• Actis M, Inoue A, Evison B, et al. Small molecule inhibitors of PCNA/PIP-box interaction suppress translesion DNA synthesis. Bioorg Med Chem. 2013;21(7):1972–1977.
   PubMed Web of Science ®Google Scholar
• Pastwa E, Poplawski T, Lewandowska U, et al. Wortmannin potentiates the combined effect of etoposide and cisplatin in human glioma cells. Int J Biochem Cell Biol. 2014;53:423–431.
   PubMed Web of Science ®Google Scholar
• Huang F, Mazin AV. A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts. Korolev S, ed. PLoS ONE. 2014;9(6):e100993.
   PubMed Web of Science ®Google Scholar
• Teng P, Bateman NW, Darcy KM, et al. Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells. Gynecol Oncol. 2015;136(3):554–561.
   PubMed Web of Science ®Google Scholar
• Mishra AK, Dormi SS, Turchi AM, et al. Chemical inhibitor targeting the Replication Protein A-DNA interaction increases the efficacy of Pt-based chemotherapy in lung and ovarian cancer. Biochem Pharmacol. 2015;93(1):25–33.
   PubMed Web of Science ®Google Scholar
• Zanjirband M, Edmondson RJ, Lunec J. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer. Oncotarget. 2016;7(26):40115–40134.
   PubMed Web of Science ®Google Scholar
• Davar D, Beumer JH, Hamieh L, et al. Role of PARP inhibitors in cancer biology and therapy. Curr Med Chem. 2012;19(23):3907–3921.
   PubMed Web of Science ®Google Scholar
• Morra F, Luise C, Visconti R, et al. New therapeutic perspectives in CCDC6 deficient lung cancer cells. Int J Cancer. 2015;136(9):2146–2157.
   PubMed Web of Science ®Google Scholar
• Brown DP, Chin-Sinex H, Nie B, et al. Targeting superoxide dismutase 1 to overcome cisplatin resistance in human ovarian cancer. Cancer Chemother Pharmacol. 2009;63(4):723–730.
   PubMed Web of Science ®Google Scholar
• Rabalski AJ, Gyenis L, Litchfield DW. Molecular pathways: emergence of protein kinase CK2 [CSNK2] as a potential target to inhibit survival and DNA damage response and repair pathways in cancer. Cells Clin Cancer Res. 2016 Jun 15;22(12):2840–2847.
   PubMed Web of Science ®Google Scholar
• Iwasa T, Okamoto I, Takezawa K, et al. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. Br J Cancer. 2010;103(1):36–42.
   PubMed Web of Science ®Google Scholar
• Bhatkar D, Kumar J, Purohit S, et al. ATM kinase inhibitor KU-55933 contribution in cisplatin mediated HeLa proliferation. Int J Pharmacol Toxicol. 2016;4(2):201–207*.
   Google Scholar